Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/46479
Title: Hematologic malignancies associated with mediastinal germ cell tumors: 10 years' experience at Thailand's national pediatric tertiary referral center
Authors: Panjarat Sowithayasakul
Phakatip Sinlapamongkolkul
Jitsupa Treetipsatit
Nassawee Vathana
Nattee Narkbunnam
Kleebsabai Sanpakit
Jassada Buaboonnam
Faculty of Medicine, Thammasat University
Mahidol University
Srinakharinwirot University
Departments of Pathology
Keywords: Medicine
Issue Date: 1-Aug-2018
Citation: Journal of Pediatric Hematology/Oncology. Vol.40, No.6 (2018), 450-455
Abstract: © 2018 Wolters Kluwer Health, Inc. All rights reserved. Mediastinal germ cell tumor (MGCT), which accounts for 1% to 3% of extragonadal germ cell tumors, has unique manifestations; it is associated with several types of hematologic malignancy, particularly myeloid neoplasm. The aim of this study was to report the 10-year incidence, clinical characteristics, and outcomes of MGCT at Thailand's national pediatric tertiary referral center. This retrospective study included patients diagnosed with MGCT at the Department of Pediatrics, Siriraj Hospital during 2005 to 2014. Eight patients (all male) were diagnosed with MGCT. Five of 8 patients were found to have hematologic abnormalities. Three patients were diagnosed with acute myeloid leukemia (AML) (one patient with M1, another having M7, and the other with M0). Another patient had mixed MGCT with mediastinal myeloid sarcoma (MMS). The other patient had malignancy-associated hemophagocytic lymphohistiocytosis syndrome (M-HLH). Isochromosome 12p was detected in 3 patients (AML [2], mixed MGCT/MMS [1]). Four of 5 patients with hematologic abnormalities died of hematologic abnormalities or treatment complication (AML [3], M-HLH [1]). One patient with mixed MGCT/MMS survived with chemotherapy. All patients with AML and MMS were nonseminomatous MGCT and the onset of myeloid malignancies were within 1 year after the diagnosis of MGCT. Associated hematologic malignancies should be suspected in MGCT with abnormal blood count or hematologic symptoms. Isochromosome 12p was the most common cytogenetic finding in MGCT-associated myeloid malignancies patients. Those with nonseminomatous MGCT should have their blood count carefully monitored especially during the first year after the diagnosis of MGCT. Better treatment alternatives for MGCT with associated hematologic malignancies are warranted to ameliorate adverse outcomes.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85048282530&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/46479
ISSN: 15363678
10774114
Appears in Collections:Scopus 2018

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.